Dehydrocorydaline (nitrate)

Dehydrocorydaline nitrate (13-Methylpalmatine nitrate) is an alkaloid. Dehydrocorydaline regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP[1]. Dehydrocorydaline nitrate elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities.[2]. Dehydrocorydaline nitrate shows strong anti-malarial effects (IC50 =38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain[3].

Product Specifications

CAS Number

[13005-09-9]

Product Name Alternative

13-Methylpalmatine (nitrate)

UNSPSC

12352005

Target

Autophagy; Bcl-2 Family; Caspase; p38 MAPK; Parasite; PARP

Type

Natural Products

Related Pathways

Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/dehydrocorydaline-nitrate.html

Purity

99.90

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

[O-][N+]([O-])=O.CC1=C(C=CC(OC)=C2OC)C2=C[N+]3=C1C4=CC(OC)=C(OC)C=C4CC3

Molecular Formula

C22H24N2O7

Molecular Weight

428.44

References & Citations

[1]Nonaka M, et al. Screening of a library of traditional Chinese medicines to identify anti-malarial compounds and extracts. Malar J. 2018 Jun 25;17 (1) :244. doi: 10.1186/s12936-018-2392-4.|[2]Xu Z, et al. Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. Am J Chin Med. 2012;40 (1) :177-85.|[3]Yoo M, et al. Dehydrocorydaline promotes myogenic differentiation via p38 MAPK activation. Mol Med Rep. 2016 Oct;14 (4) :3029-36.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture and light)

Scientific Category

Natural Products

Clinical Information

No Development Reported

Isoform

Plasmodium

Citation 01

Research Square Preprint. 2020 Dec.|Aging (Albany NY) . 2021 May 11;13 (9) :12780-12799.|Aging (Albany NY) . 2021 Oct 7;13 (19) :23133-23148.|Andrology. 2025 Jun 16.|Arthritis Res Ther. 2025 May 31;27 (1) :118.|Biochem Biophys Res Commun. 2018 May 23;499 (4) :743-750. |Biochem Biophys Res Commun. 2018 Sep 5;503 (2) :467-473. |Biochem Pharmacol. 2024 Dec;230 (Pt 1) :116574.|BMC Musculoskelet Disord. 2022 May 30;23 (1) :514.|Bone Joint Res. 2023 Nov 1;12 (11) :677-690.|Comput Math Methods Med. 2021 Aug 2:2021:3337514.|Eur J Histochem. 2025 Jan 21;69 (1) .|Eur J Pharmacol. 2021 Jun 5:900:174069.|FASEB J. 2025 Aug 31;39 (16) :e70945.|Infect Genet Evol. 2022 Jan:97:105158.|J Agric Food Chem. 2023 Oct 25;71 (42) :15538-15552.|J Cell Physiol. 2019 Dec;234 (12) :22463-22476.|J Clin Neurosci. 2020 Aug;78:365-370.|J Mol Histol. 2021 Jun;52 (3) :521-537.|J Nanobiotechnology. 2025 Jul 22;23 (1) :535.|J Nutr. 2020 Jul 1;150 (7) :1731-1737.|Mol Carcinog. 2024 Nov;63 (11) :2190-2204.|Biochem Pharmacol. 2025 May:235:116820.|Bioengineered. 2022 May;13 (5) :12847-12862.|Ecotoxicol Environ Saf. 2025 Jun 4:300:118460.|Exp Eye Res. 2023 Feb:227:109365.|Front Biosci (Landmark Ed) . 2025 Apr 25;30 (4) :25221.|Front Pharmacol. 2021 May 31:12:653272.|Genomics. 2025 Jun 1:111067.|Int Immunopharmacol. 2024 Jul 23:139:112720.|J Cardiothorac Surg. 2024 Dec 20;19 (1) :665.|J Clin Invest. 2024 Jun 18:e178303.|J Ethnopharmacol. 2024 Aug 31:118738.|J Food Sci. 2025 Apr;90 (4) :e70217.|J Inflamm Res. 2021 Sep 16;14:4669-4686.|New Phytol. 2024 May 13.|Phytomedicine. 2021 Nov:92:153740.|Respir Res. 2025 Apr 12;26 (1) :136.|Tissue Cell. 2023 Dec:85:102218.